GPNX
NOTIFICATION PROCESSED BY IB
04/04/2021
Back to search
Official data from USPTO
TIGERMED
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
14
Latest update
04/04/2021
Classification
Registered
Trademark type
Combined
Nice classes
42, 45
Filing date
06/29/2020
Registration date
01/26/2021
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/26/2021
Last transaction
01/26/2021
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
5
Owner type
99
Owner location
CN
Examiner
CIANCI, RYAN MICHAEL
Law office
M70
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
HANGZHOU TIGERMED CONSULTING CO., LTD.
Hangzhou Tigermed Pharmaceutical technology co., LTD
Representatives
Hangzhou copyright protection and management center
Technical classification
Nice Classes
Class 42Class 45
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Technical research in the field of pharmaceutical studies; research on the subject of pharmaceuticals; pharmaceutical research services; research in the field of cosmeticspharmaceuticals and new products; consulting services in the fields of biotechnologypharmaceutical research and development and genetic science; providing medical and scientific research information in the fields of pharmaceuticals and genetics; research and development in the pharmaceutical and biotechnology fields; laboratory research services relating to pharmaceuticals; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; development of pharmaceutical preparations and medicines; scientific research for medical purposes in the area of cancerous diseases; conducting clinical trials for others scientific research; medical research; chemicalbiochemicalbiological and bacteriological research and analysis; research and development services in the field of antibodies; blood analysis services; medical laboratory services; biomedical research services; testing of chemicals; computer programming in the medical field
Class 45
Chaperoning; online social networking services; intellectual property consultancy; licensing of software for management of intellectual property legal services; licensing of intellectual property rights; legal administration of licences
Publications
History of USPTO decisions and trademark events.
14 publications found
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
02/27/2021
XXCR
GENERIC MADRID TRANSACTION CREATED
02/27/2021
GPAR
GRANT OF PROTECTION CREATED, TO BE SENT TO IB
02/25/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
01/26/2021
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
11/27/2020
PUBO
PUBLISHED FOR OPPOSITION
11/10/2020
NPUB
NOTICE OF PUBLICATION
10/21/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/02/2020
DOCK
ASSIGNED TO EXAMINER
10/01/2020
MAFR
APPLICATION FILING RECEIPT MAILED
08/11/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/05/2020
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
08/04/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
07/30/2020
Continuous trademark protection
Get notified about every new filing that threatens TIGERMED or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.